OBIO is proud to announce a national call for applications from health science companies, seeking Series A and beyond investments, to present at the 2019 Niagara Investment Summit, February 20-22, 2019.
The Summit will bring 30 of Canada’s most promising health science companies to Niagara-on-the-Lake to present to and meet with global investors. The Summit will feature keynote presentations and panel discussions from world-leading scientific and business experts including Tom Lynch, former Chairman of Icon plc, Founder of Warner Chilcott, former CFO of Elan plc, Chairman of Evofem Biosciences and Non-Executive Director of GW Pharma, and Dr. Duncan Stewart, President and Scientific Director, Ontario Institute for Regenerative Medicine, Executive Vice-President of Research at The Ottawa Hospital, and CEO and Scientific Director of the Ottawa Hospital Research Institute.
This year’s Summit will highlight three fast-growing sectors:
AI in Health
New Frontiers in Medicine
Digital Health and Diagnostics
Companies selected to participate in the 2019 Niagara Investment Summit will be on a rolling basis and presentation spots are limited. Interested companies should send an email to Christina Yeh (email@example.com) and include a non-confidential pitch deck (15 slides maximum), demonstrating how your company fits within the theme of the Summit.
Selected companies are responsible for the conference fee of $2,500 which includes:
· Full registration for one company representative
· An opportunity to pitch and hold one-on-one meetings with leading global investors
· Attendance at a health science CEO roundtable dinner discussion
· Two nights’ accommodation
· Breakfast, lunch and dinner for the duration of the conference
OBIO 2019 Niagara Investment Summit Eligibility
Companies based in Canada focused on developing health science products or services including but not limited to: therapeutics, medical devices, diagnostics, or digital health which fit into the themes of the 2019 Niagara Investment Summit.
Companies based in Canada seeking to raise Series A and beyond investment.